MCID: TNG009
MIFTS: 59

Tongue Squamous Cell Carcinoma malady

Categories: Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Tongue Squamous Cell Carcinoma

Aliases & Descriptions for Tongue Squamous Cell Carcinoma:

Name: Tongue Squamous Cell Carcinoma 38 12 14
Squamous Cell Carcinoma of Tongue 69
Carcinoma, Squamous Cell 42

Classifications:



External Ids:

Disease Ontology 12 DOID:0050865
MeSH 42 D002294
NCIt 47 C2929
UMLS 69 C0007137

Summaries for Tongue Squamous Cell Carcinoma

Disease Ontology : 12 A head and neck squamous cell carcinoma that is located in the tongue.

MalaCards based summary : Tongue Squamous Cell Carcinoma, also known as squamous cell carcinoma of tongue, is related to squamous cell carcinoma of the oral tongue and squamous cell carcinoma. An important gene associated with Tongue Squamous Cell Carcinoma is DND1 (DND MicroRNA-Mediated Repression Inhibitor 1), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Cisplatin and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and t cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Tongue Squamous Cell Carcinoma

Diseases related to Tongue Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma of the oral tongue 11.1
2 squamous cell carcinoma 11.0
3 clear cell adenofibroma 10.3 CDKN2A TP53
4 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
5 chondrodysplasia punctata, rhizomelic, type 3 10.3 CASP3 TP53
6 congenital sucrase-isomaltase deficiency without sucrose intolerance 10.3 NOTCH1 TP53
7 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
8 pericardium leiomyoma 10.3 CDKN2A TP53
9 linitis plastica 10.3 CDH1 TP53
10 brain stem medulloblastoma 10.2 CDKN2A NOTCH1 TP53
11 fallopian tube adenocarcinoma 10.2 CASP3 CDKN2A TP53
12 cutaneous adenocystic carcinoma 10.2 BSG NOTCH1 TP53
13 acute tricyclic antidepressant poisoning 10.2 MMP2 MMP9
14 neuropathy, hereditary sensory, type id 10.2 MMP14 MMP2
15 striated muscle rhabdoid tumor 10.2 CDKN2A MMP2 MMP9
16 diffuse large b-cell lymphoma 10.2 HIF1A MMP1 MMP9
17 adenoid squamous cell carcinoma 10.2 CDKN2A MMP2 MMP9
18 anisomastia 10.2 MMP14 MMP2
19 breast leiomyoma 10.2 CDKN2A MMP2 TP53
20 spastic hemiplegia 10.2 HIF1A MMP1 MMP9
21 kleptomania 10.2 MMP1 MMP2 MMP9
22 estrogen-receptor positive breast cancer 10.2 CDH1 CDKN2A TP53
23 fallopian tube leiomyosarcoma 10.2 CDH1 CDKN2A TP53
24 pyomyositis 10.1 CDH1 CDKN2A TP53
25 retinal drusen 10.1 MMP2 MMP9 NOTCH1
26 papillary transitional carcinoma 10.1 CASP3 CDH1 TP53
27 onychocytic matricoma 10.1 MMP1 MMP2 MMP9
28 lower lip cancer 10.1 CASP3 MMP2 MMP9
29 melanoma metastasis 10.1 BMI1 CASP3 CDKN2A TP53
30 laryngostenosis 10.1 MMP1 MMP2 MMP9
31 adenocarcinoma in situ 10.1 MMP14 MMP2 MMP9
32 breast abscess 10.1 MMP1 MMP2 MMP9
33 dental caries 10.1 CDH1 MMP2 TP53
34 chronic polyneuropathy 10.1 MMP2 MMP9 NOTCH1
35 nasal cavity disease 10.1 CDH1 MMP2 TP53
36 progesterone-receptor positive breast cancer 10.1 CDH1 CDKN2A TP53
37 metagonimiasis 10.1 MMP2 TP53 VEGFC
38 marginal zone b-cell lymphoma 10.1 CDKN2A MMP2 MMP9 TP53
39 maxillary neoplasm 10.1 CDH1 MMP2 MMP9
40 breast papillary carcinoma 10.1 CDH1 MMP2 MMP9
41 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.1 CDKN2A MMP2 MMP9 TP53
42 mitochondrial encephalomyopathy 10.1 CDKN2A MMP14 MMP2 TP53
43 sternum lymphoma 10.1 CDH2 CDKN2A TP53
44 connective tissue benign neoplasm 10.1 CASP3 CDH1 CDKN2A TP53
45 hypoxia 10.1
46 glucosephosphate isomerase deficiency 10.1 CDKN2A MMP2 MMP9 TP53
47 senile atrophy of choroid 10.1 CASP3 MMP1 MMP2 MMP9
48 adrenal cortical carcinoma 10.1 CASP3 CDH1 CDKN2A TP53
49 subglottis neoplasm 10.1 CDKN2A MMP1 MMP14 MMP2
50 endotheliitis 10.0

Graphical network of the top 20 diseases related to Tongue Squamous Cell Carcinoma:



Diseases related to Tongue Squamous Cell Carcinoma

Symptoms & Phenotypes for Tongue Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Tongue Squamous Cell Carcinoma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 CASP3 CDH1 CDH2 CDKN2A CTNNB1 HIF1A
2 homeostasis/metabolism MP:0005376 10.37 CASP3 CDH1 CDH2 CDKN2A CTNNB1 HIF1A
3 growth/size/body region MP:0005378 10.36 BSG CASP3 CDH1 CDH2 CDKN2A CTNNB1
4 immune system MP:0005387 10.36 SNAI2 TP53 VEGFC BSG CASP3 CDH1
5 mortality/aging MP:0010768 10.35 BSG CASP3 CDH1 CDH2 CDKN2A CTNNB1
6 endocrine/exocrine gland MP:0005379 10.3 CASP3 CDH1 CDKN2A CTNNB1 DND1 HIF1A
7 cellular MP:0005384 10.29 CASP3 CDH1 CDH2 CDKN2A CTNNB1 HIF1A
8 hematopoietic system MP:0005397 10.28 BSG CASP3 CDKN2A CTNNB1 HIF1A MMP14
9 digestive/alimentary MP:0005381 10.27 TP53 CASP3 CDH1 CDKN2A CTNNB1 HIF1A
10 embryo MP:0005380 10.22 NOTCH1 SNAI2 TP53 CDH1 CDH2 CDKN2A
11 craniofacial MP:0005382 10.19 CASP3 CTNNB1 HIF1A MMP14 MMP2 NOTCH1
12 integument MP:0010771 10.19 MMP14 MMP9 NOTCH1 SNAI2 TP53 CASP3
13 muscle MP:0005369 10.16 NOTCH1 TP53 CASP3 CDH2 CDKN2A CTNNB1
14 nervous system MP:0003631 10.14 CASP3 CDH2 CDKN2A CTNNB1 HIF1A MMP14
15 neoplasm MP:0002006 10.13 MMP1 MMP2 MMP9 NOTCH1 TP53 CDH1
16 reproductive system MP:0005389 9.96 BSG CASP3 CDH1 CDKN2A CTNNB1 DND1
17 renal/urinary system MP:0005367 9.87 MMP14 MMP9 NOTCH1 TP53 CASP3 CTNNB1
18 pigmentation MP:0001186 9.85 CASP3 CDKN2A CTNNB1 NOTCH1 SNAI2 TP53
19 respiratory system MP:0005388 9.85 BSG CASP3 CDKN2A CTNNB1 HIF1A MMP14
20 skeleton MP:0005390 9.65 CASP3 CDKN2A CTNNB1 HIF1A MMP14 MMP2
21 vision/eye MP:0005391 9.32 CASP3 CDKN2A CTNNB1 HIF1A MMP14 MMP2

Drugs & Therapeutics for Tongue Squamous Cell Carcinoma

Drugs for Tongue Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
3
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
4
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
5
Pilocarpine Approved Phase 3 54-71-7, 92-13-7 5910
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
8
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
9
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
10
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
11
Doxepin Approved Phase 3 1668-19-5 667477 667468
12
Bleomycin Approved Phase 3 11056-06-7 5360373
13
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
14 Interleukin-2 Phase 3
15 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
16 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
17 Anti-HIV Agents Phase 3,Phase 2
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1
22 Anti-Retroviral Agents Phase 3,Phase 2
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antiviral Agents Phase 3,Phase 2
26 pancreatic polypeptide Phase 3
27 Analgesics Phase 3,Phase 2
28 Mitogens Phase 3,Phase 2,Phase 1
29 Cholinergic Agents Phase 3
30 Adjuvants, Anesthesia Phase 3
31 Narcotics Phase 3
32 Neurotransmitter Agents Phase 3,Phase 2
33 Analgesics, Opioid Phase 3
34 Anesthetics Phase 3,Phase 2
35 Vaccines Phase 3,Phase 1
36 Anesthetics, General Phase 3
37 Anesthetics, Intravenous Phase 3
38 Peripheral Nervous System Agents Phase 3,Phase 2
39 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
40 Immunoglobulins Phase 3,Phase 2,Phase 1
41 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
43 Antibodies Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 3,Phase 2
45 Central Nervous System Depressants Phase 3,Phase 2
46
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
47 Neuromuscular Agents Phase 3,Phase 2
48 Neuromuscular Blocking Agents Phase 3,Phase 2
49 Neuromuscular Depolarizing Agents Phase 3,Phase 2
50 Histamine Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 102)
id Name Status NCT ID Phase
1 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
2 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
3 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
4 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
5 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
7 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
8 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
9 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
10 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3
11 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
12 Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma Not yet recruiting NCT02984410 Phase 3
13 Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma Suspended NCT00198328 Phase 3
14 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3
15 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2
16 Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Unknown status NCT00851877 Phase 1, Phase 2
17 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2
18 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2
19 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
20 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2
21 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2
22 Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery Completed NCT00665392 Phase 2
23 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Completed NCT01084083 Phase 2
24 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2
25 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2
26 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2
27 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2
28 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2
29 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2
30 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2
31 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2
32 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2
33 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2
34 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2
35 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00423930 Phase 2
36 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
37 Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Recruiting NCT02985255 Phase 2
38 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2
39 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2
40 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02295540 Phase 1, Phase 2
41 Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design Recruiting NCT02128906 Phase 2
42 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
43 Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Active, not recruiting NCT01312350 Phase 2
44 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02035527 Phase 1, Phase 2
45 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Active, not recruiting NCT01316757 Phase 2
46 Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Active, not recruiting NCT02254278 Phase 2
47 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Active, not recruiting NCT01469429 Phase 1, Phase 2
48 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2
49 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Not yet recruiting NCT01760811 Phase 1, Phase 2
50 Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events Not yet recruiting NCT03107182 Phase 2

Search NIH Clinical Center for Tongue Squamous Cell Carcinoma

Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Tongue Squamous Cell Carcinoma

Anatomical Context for Tongue Squamous Cell Carcinoma

MalaCards organs/tissues related to Tongue Squamous Cell Carcinoma:

39
Tongue, Lymph Node, T Cells, Skeletal Muscle, Endothelial, Neutrophil, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Tongue Squamous Cell Carcinoma:

18
The Tongue

Publications for Tongue Squamous Cell Carcinoma

Articles related to Tongue Squamous Cell Carcinoma:

(show top 50) (show all 258)
id Title Authors Year
1
Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. ( 27932243 )
2017
2
miR-373-3p Targets DKK1 to Promote EMT-Induced Metastasis via the Wnt/I^-Catenin Pathway in Tongue Squamous Cell Carcinoma. ( 28337453 )
2017
3
Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma. ( 28367232 )
2017
4
Radiosensitization of oral tongue squamous cell carcinoma by nanosecond pulsed electric fields (nsPEFs). ( 27676191 )
2017
5
Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma. ( 27821487 )
2017
6
hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. ( 28535002 )
2017
7
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma. ( 28314297 )
2017
8
Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway. ( 27831944 )
2017
9
Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. ( 28411370 )
2017
10
MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro. ( 27773646 )
2017
11
Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miRa89375. ( 27878285 )
2017
12
Occult level IV metastases in clinically node-negative patients with oral tongue squamous cell carcinoma. ( 27095552 )
2016
13
BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma. ( 27722045 )
2016
14
A Minimal DNA Methylation Signature in Oral Tongue Squamous Cell Carcinoma Links Altered Methylation with Tumor Attributes. ( 27288358 )
2016
15
HMGA2 is associated with the aggressiveness of tongue squamous cell carcinoma. ( 27809392 )
2016
16
The downregulation of ANGPTL4 inhibits the migration and proliferation of tongue squamous cell carcinoma. ( 27505034 )
2016
17
Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma. ( 27614428 )
2016
18
The anterolateral thigh flap for soft tissue reconstruction in patients with tongue squamous cell carcinoma. ( 27514796 )
2016
19
miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin. ( 27698823 )
2016
20
MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma. ( 27561985 )
2016
21
High relative density of lymphatic vessels predicts poor survival in tongue squamous cell carcinoma. ( 27328960 )
2016
22
Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. ( 26426362 )
2016
23
Proapoptotic Activity of Propolis and Their Components on Human Tongue Squamous Cell Carcinoma Cell Line (CAL-27). ( 27281369 )
2016
24
Efficacy of Elective Neck Dissection in T1/T2N0M0 Oral Tongue Squamous Cell Carcinoma: A Population-Based Analysis. ( 27165672 )
2016
25
Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma. ( 27582550 )
2016
26
Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transition. ( 27613832 )
2016
27
Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin-angiotensin system. ( 27371611 )
2016
28
miR-183 Modulates Cell Apoptosis and Proliferation in Tongue Squamous Cell Carcinoma SCC25 Cell Line. ( 28281960 )
2016
29
HPV Infection and Prognostic Factors of Tongue Squamous Cell Carcinoma in Different Ethnic Groups from Geographically Closed Cohort in Xinjiang, China. ( 27034835 )
2016
30
Correlation between clinical and MRI assessment of depth of invasion in oral tongue squamous cell carcinoma. ( 27876067 )
2016
31
Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma. ( 26667395 )
2016
32
A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways. ( 27644244 )
2016
33
Interleukin-17A promotes tongue squamous cell carcinoma metastasis through activating miR-23b/versican pathway. ( 28035060 )
2016
34
Immunohistochemical expression of secreted frizzled receptor protein 1 in the invasive front of tongue squamous cell carcinoma. ( 26921060 )
2016
35
TGFI^1-Smad3-Jagged1-Notch1-Slug signaling pathway takes part in tumorigenesis and progress of tongue squamous cell carcinoma. ( 26764364 )
2016
36
Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: a Matched Case-Control Study. ( 27737535 )
2016
37
p53 Expression Helps Identify High Risk Oral Tongue Pre- malignant Lesions and Correlates with Patterns of Invasive Tumour Front and Tumour Depth in Oral Tongue Squamous Cell Carcinoma Cases. ( 26838208 )
2016
38
14-3-3IP silencing retards tongue squamous cell carcinoma progression by inhibiting cell survival and migration. ( 27080223 )
2016
39
Hexokinase 2 enhances the metastatic potential of tongue squamous cell carcinoma via the SOD2-H2O2 pathway. ( 27926482 )
2016
40
FRMD4A: A potential therapeutic target for the treatment of tongue squamous cell carcinoma. ( 27666346 )
2016
41
Development and validation of Raman spectroscopic classification models to discriminate tongue squamous cell carcinoma from non-tumorous tissue. ( 27531871 )
2016
42
The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. ( 26982018 )
2016
43
Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma. ( 27095085 )
2016
44
Phosphorylated Epidermal Growth Factor Receptor Expression Is Associated With Clinicopathologic Parameters and Patient Survival in Mobile Tongue Squamous Cell Carcinoma. ( 27657462 )
2016
45
miR-24 promotes the proliferation, migration and invasion in human tongue squamous cell carcinoma by targeting FBXW7. ( 27350307 )
2016
46
TUC338 Overexpression Leads to Enhanced Proliferation and Reduced Apoptosis in Tongue Squamous Cell Carcinoma Cells InA Vitro. ( 27637778 )
2016
47
Decreased expression of Beclina891 is significantly associated with a poor prognosis in oral tongue squamous cell carcinoma. ( 27356955 )
2016
48
Overexpression long non-coding RNA LINC00673 is associated with poor prognosis and promotes invasion and metastasis in tongue squamous cell carcinoma. ( 28039470 )
2016
49
Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-I_B signaling pathway. ( 26799420 )
2016
50
Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. ( 26650483 )
2016

Variations for Tongue Squamous Cell Carcinoma

ClinVar genetic disease variations for Tongue Squamous Cell Carcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 DDR2 NM_001014796.1(DDR2): c.2304T> A (p.Ser768Arg) single nucleotide variant Pathogenic rs267598140 GRCh37 Chromosome 1, 162748390: 162748390

Cosmic variations for Tongue Squamous Cell Carcinoma:

9 (show top 50) (show all 68)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11196 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.734G>T p.G245V 13
2 COSM10656 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.742C>T p.R248W 13
3 COSM10834 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.711G>A p.M237I 13
4 COSM10867 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.797G>A p.G266E 13
5 COSM10790 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.455C>T p.P152L 13
6 COSM10905 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.451C>T p.P151S 13
7 COSM10654 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.637C>T p.R213* 13
8 COSM44262 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.808T>C p.F270L 13
9 COSM43708 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 13
10 COSM43621 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.809T>G p.F270C 13
11 COSM10648 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.524G>A p.R175H 13
12 COSM43841 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.560-1G>T p.? 13
13 COSM44351 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.572C>T p.P191L 13
14 COSM45135 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.673-1G>T p.? 13
15 COSM10687 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.527G>A p.C176Y 13
16 COSM10992 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.844C>G p.R282G 13
17 COSM44411 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.608T>A p.V203E 13
18 COSM10939 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.832C>T p.P278S 13
19 COSM44523 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.863A>G p.N288S 13
20 COSM43814 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.587G>C p.R196P 13
21 COSM10859 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.814G>T p.V272L 13
22 COSM10660 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.818G>A p.R273H 13
23 COSM10704 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.844C>T p.R282W 13
24 COSM10663 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.916C>T p.R306* 13
25 COSM44424 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.590T>A p.V197E 13
26 COSM10724 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.839G>C p.R280T 13
27 COSM6932 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.733G>A p.G245S 13
28 COSM11066 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.578A>T p.H193L 13
29 COSM10771 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.749C>T p.P250L 13
30 COSM43947 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 13
31 COSM11073 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 13
32 COSM45132 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.783-2A>G p.? 13
33 COSM11450 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.644G>T p.S215I 13
34 COSM43963 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.396G>C p.K132N 13
35 COSM10662 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 13
36 COSM44567 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.647T>C p.V216A 13
37 COSM45275 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.559G>T p.G187C 13
38 COSM43695 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.748C>T p.P250S 13
39 COSM10726 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.856G>A p.E286K 13
40 COSM10727 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.438G>A p.W146* 13
41 COSM44073 TP53 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.374C>A p.T125K 13
42 COSM777 PIK3CA upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.3145G>A p.G1049S 13
43 COSM21436 PIK3CA upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.1028A>G p.Y343C 13
44 COSM763 PIK3CA upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 13
45 COSM1667036 NOTCH2 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.337C>T p.R113* 13
46 COSM1667029 NOTCH1 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.666C>A p.C222* 13
47 COSM1667030 NOTCH1 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.1237G>A p.V413M 13
48 COSM4654463 NOTCH1 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.1239G>A p.V413V 13
49 COSM3215939 NOTCH1 upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.5362G>A p.G1788S 13
50 COSM521 KRAS upper aerodigestive tract,tongue,carcinoma,squamous cell carcinoma c.35G>A p.G12D 13

Expression for Tongue Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Tongue Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 30)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Oral Cavity + 6.95 0.000
2 TMPRSS11B transmembrane protease, serine 11B Oral Cavity - 5.73 0.000
3 MAL mal, T-cell differentiation protein Oral Cavity - 5.07 0.000
4 CRNN cornulin Oral Cavity - 4.97 0.000
5 KRT13 keratin 13, type I Oral Cavity - 4.67 0.001
6 MYH2 myosin, heavy chain 2, skeletal muscle, adult Oral Cavity - 4.12 0.005
7 PTHLH parathyroid hormone-like hormone Oral Cavity + 4.09 0.000
8 KRT17 keratin 17, type I Oral Cavity + 3.76 0.000
9 CXCL12 chemokine (C-X-C motif) ligand 12 Oral Cavity - 3.73 0.000
10 LAMC2 laminin, gamma 2 Oral Cavity + 3.68 0.000
11 CLCA4 chloride channel accessory 4 Oral Cavity - 3.65 0.000
12 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Oral Cavity + 3.44 0.000
13 LDB3 LIM domain binding 3 Oral Cavity - 3.41 0.003
14 MMP3 matrix metallopeptidase 3 Oral Cavity + 3.39 0.000
15 CLU clusterin Oral Cavity - 3.38 0.000
16 WDR66 WD repeat domain 66 Oral Cavity + 3.37 0.000
17 GALNT16 polypeptide N-acetylgalactosaminyltransferase 16 Oral Cavity - 3.36 0.000
18 PRR9 proline rich 9 Oral Cavity + 3.34 0.004
19 CXCL8 chemokine (C-X-C motif) ligand 8 Oral Cavity + 3.33 0.000
20 CRISP3 cysteine-rich secretory protein 3 Oral Cavity - 3.23 0.010
21 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Oral Cavity - 3.21 0.000
22 SPINK5 serine peptidase inhibitor, Kazal type 5 Oral Cavity - 3.20 0.002
23 S100A7A S100 calcium binding protein A7A Oral Cavity + 3.15 0.001
24 IFI6 interferon, alpha-inducible protein 6 Oral Cavity + 3.13 0.000
25 INHBA inhibin, beta A Oral Cavity + 3.13 0.001
26 KRT4 keratin 4, type II Oral Cavity - 3.11 0.000
27 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Oral Cavity - 3.10 0.000
28 FAM3B family with sequence similarity 3, member B Oral Cavity - 3.08 0.007
29 EPPK1 epiplakin 1 Oral Cavity + 3.07 0.000
30 SPRR3 small proline-rich protein 3 Oral Cavity - 3.06 0.025
Search GEO for disease gene expression data for Tongue Squamous Cell Carcinoma.

Pathways for Tongue Squamous Cell Carcinoma

Pathways related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CASP3 CDH1 CDH2 CDKN2A CTNNB1 HIF1A
2
Show member pathways
13.28 CASP3 CDH1 CDH2 CTNNB1 NOTCH1 SNAI2
3
Show member pathways
13.01 CDH1 CDKN2A CTNNB1 MMP2 MMP9 NOTCH1
4
Show member pathways
12.79 CASP3 CDH1 CTNNB1 HIF1A TP53
5
Show member pathways
12.78 CASP3 CTNNB1 MMP14 MMP2 MMP9
6
Show member pathways
12.71 BSG CASP3 CDH1 MMP1 MMP14 MMP2
7
Show member pathways
12.56 CASP3 CDH1 CTNNB1 MMP2 MMP9 TP53
8 12.5 BMI1 CASP3 CDKN2A MMP9 NOTCH1 TP53
9 12.41 CDH1 CDH2 CTNNB1 TP53
10
Show member pathways
12.35 CASP3 CDH1 CTNNB1 TP53
11
Show member pathways
12.25 CASP3 HIF1A MMP1 TP53
12 12.22 CASP3 CTNNB1 HIF1A MMP2 MMP9 TP53
13 12.15 CASP3 CDH1 CTNNB1 MMP1 TP53
14 12.08 CTNNB1 MMP2 MMP9 TP53
15 12.07 CASP3 CDH1 CDH2 CTNNB1 NOTCH1
16 11.99 CTNNB1 HIF1A NOTCH1 TP53
17 11.95 CASP3 MMP14 MMP9 VEGFC
18 11.95 HIF1A MMP1 MMP2 MMP9 TP53
19 11.94 BMI1 CDKN2A MMP14 TP53
20 11.92 CASP3 CDH1 CDKN2A CTNNB1 HIF1A MMP1
21 11.89 CASP3 MMP2 VEGFC
22 11.88 CDH1 CDH2 CTNNB1 NOTCH1 SNAI2
23
Show member pathways
11.85 CTNNB1 HIF1A VEGFC
24
Show member pathways
11.85 BSG MMP1 MMP14 MMP2 MMP9
25 11.78 BMI1 MMP9 TP53
26 11.78 CASP3 CDH1 CTNNB1 MMP1 MMP14 MMP2
27 11.74 CDH2 CTNNB1 NOTCH1
28 11.74 HIF1A MMP2 MMP9 NOTCH1 VEGFC
29 11.74 BSG CDH1 CDH2 CTNNB1 MMP14 MMP2
30 11.73 CASP3 CDKN2A TP53
31 11.72 CDH1 CTNNB1 SNAI2
32 11.7 CDKN2A CTNNB1 MMP2 TP53
33 11.66 CASP3 MMP2 MMP9
34 11.66 MMP1 MMP14 MMP2 MMP9
35 11.66 CDH1 CTNNB1 MMP2 MMP9 SNAI2
36
Show member pathways
11.65 MMP1 MMP2 MMP9
37 11.61 CASP3 CTNNB1 MMP9
38 11.6 CDH1 CDKN2A MMP1 MMP2 MMP9 TP53
39 11.59 CDKN2A HIF1A TP53 VEGFC
40 11.54 CDKN2A MMP2 TP53
41 11.54 CASP3 HIF1A MMP1 TP53
42 11.54 CASP3 HIF1A MMP14 MMP2 MMP9
43 11.5 CDH1 CDH2 MMP9
44 11.49 CTNNB1 NOTCH1 VEGFC
45 11.49 CASP3 MMP1 TP53
46 11.42 CDH1 CDH2 CTNNB1
47 11.34 MMP1 MMP2 MMP9
48 11.26 CDH1 CTNNB1 TP53
49 11.03 CDH1 CDH2 SNAI2
50 11 BSG MMP1 MMP9

GO Terms for Tongue Squamous Cell Carcinoma

Cellular components related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell adherens junction GO:0005913 9.5 CDH1 CDH2 CTNNB1
2 apical junction complex GO:0043296 9.37 CDH1 CTNNB1
3 fascia adherens GO:0005916 9.26 CDH2 CTNNB1
4 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
5 adherens junction GO:0005912 9.13 CDH2 CTNNB1 NOTCH1
6 catenin complex GO:0016342 8.8 CDH1 CDH2 CTNNB1

Biological processes related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 CDKN2A CTNNB1 NOTCH1 TP53 VEGFC
2 positive regulation of transcription, DNA-templated GO:0045893 9.95 CDH1 CDKN2A CTNNB1 HIF1A NOTCH1 TP53
3 regulation of gene expression GO:0010468 9.88 BMI1 CTNNB1 HIF1A NOTCH1
4 positive regulation of cell migration GO:0030335 9.86 MMP14 MMP9 NOTCH1 SNAI2
5 lung development GO:0030324 9.81 CTNNB1 MMP14 NOTCH1
6 angiogenesis GO:0001525 9.8 HIF1A MMP14 MMP2 NOTCH1 VEGFC
7 positive regulation of apoptotic process GO:0043065 9.73 CASP3 CDKN2A CTNNB1 MMP9 NOTCH1 TP53
8 positive regulation of neuron apoptotic process GO:0043525 9.72 CASP3 CTNNB1 TP53
9 response to hypoxia GO:0001666 9.72 CASP3 HIF1A MMP14 MMP2 VEGFC
10 embryo implantation GO:0007566 9.7 BSG MMP2 MMP9
11 collagen catabolic process GO:0030574 9.67 MMP1 MMP14 MMP2 MMP9
12 cell fate specification GO:0001708 9.65 CTNNB1 NOTCH1
13 regulation of osteoblast differentiation GO:0045667 9.65 CTNNB1 SNAI2
14 positive regulation of protein oligomerization GO:0032461 9.64 MMP1 TP53
15 epithelial to mesenchymal transition involved in endocardial cushion formation GO:0003198 9.63 NOTCH1 SNAI2
16 morphogenesis of embryonic epithelium GO:0016331 9.63 CTNNB1 VEGFC
17 adherens junction organization GO:0034332 9.63 CDH1 CDH2 CTNNB1
18 entry of bacterium into host cell GO:0035635 9.62 CDH1 CTNNB1
19 replicative senescence GO:0090399 9.62 CDKN2A TP53
20 negative regulation of oligodendrocyte differentiation GO:0048715 9.61 CTNNB1 NOTCH1
21 positive regulation of endothelial cell differentiation GO:0045603 9.61 CTNNB1 NOTCH1
22 endodermal cell differentiation GO:0035987 9.61 MMP14 MMP2 MMP9
23 cardiac ventricle morphogenesis GO:0003208 9.59 HIF1A NOTCH1
24 somatic stem cell division GO:0048103 9.58 CDKN2A NOTCH1
25 cellular response to indole-3-methanol GO:0071681 9.54 CDH1 CTNNB1
26 cell migration involved in endocardial cushion formation GO:0003273 9.51 NOTCH1 SNAI2
27 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.49 HIF1A NOTCH1
28 epithelial to mesenchymal transition GO:0001837 9.46 CTNNB1 HIF1A NOTCH1 SNAI2
29 positive regulation of neuroblast proliferation GO:0002052 9.26 CTNNB1 HIF1A NOTCH1 VEGFC
30 extracellular matrix disassembly GO:0022617 9.1 BSG CDH1 MMP1 MMP14 MMP2 MMP9
31 negative regulation of apoptotic process GO:0043066 10 CASP3 HIF1A MMP9 SNAI2 TP53

Molecular functions related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.88 CASP3 MMP1 MMP14 MMP2 MMP9
2 serine-type endopeptidase activity GO:0004252 9.76 MMP1 MMP14 MMP2 MMP9
3 protein kinase binding GO:0019901 9.65 CDH2 CDKN2A CTNNB1 HIF1A TP53
4 protein phosphatase binding GO:0019903 9.5 CDH2 CTNNB1 TP53
5 metallopeptidase activity GO:0008237 9.46 MMP1 MMP14 MMP2 MMP9
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.43 CASP3 CDKN2A
7 gamma-catenin binding GO:0045295 9.4 CDH1 CDH2
8 alpha-catenin binding GO:0045294 9.37 CDH2 CTNNB1
9 enzyme binding GO:0019899 9.35 CDH2 CTNNB1 HIF1A NOTCH1 TP53
10 metalloendopeptidase activity GO:0004222 8.92 MMP1 MMP14 MMP2 MMP9

Sources for Tongue Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....